In an open-label phase II trial , patients with advanced NSCLC , EGFR wild-type or unknown , PS @-@ , in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib @ mg/d ( day @-@ ) + docetaxel ( @ mg/m ( @ ) d@ ) ( arm ED ) or docetaxel ( @ mg/m ( @ ) d@ ) alone ( arm D ) ( @-day cycle ) .